• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Ambros Reinhard J.

    7/23/25 7:36:52 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNTX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Ambros Reinhard J.

    (Last) (First) (Middle)
    C/O REIN THERAPEUTICS, INC
    12407 N. MOPAC EXPY. SUITE 250 #390

    (Street)
    AUSTIN TX 78758

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Rein Therapeutics, Inc. [ RNTX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/23/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $1.55 07/23/2025 A 17,500 (1) 07/22/2035 Common Stock 17,500 $0 17,500 D
    Explanation of Responses:
    1. This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.
    /s/ Brian Windsor, attorney-in-fact for Reinhard J. Ambros 07/23/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RNTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RNTX

    DatePrice TargetRatingAnalyst
    9/22/2025$10.00Buy
    H.C. Wainwright
    1/28/2025$8.00Buy
    Rodman & Renshaw
    More analyst ratings

    $RNTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF

    AUSTIN, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that a new preprint has been posted to medRxiv describing clinical and translational findings from an inhaled, dose-escalation study of Rein's lead drug candidate, LTI-03, in idiopathic pulmonary fibrosis (IPF). The preprint, titled "Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation Study," was authored by an international team of investigators, including Philip L. Molyneaux, MD, Nikhil A. Hi

    11/6/25 7:30:00 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

    FDA lifts clinical hold following review of Company's Complete Response submission.Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites.Early data suggests that LTI-03 may not only slow fibrosis but also promote lung healing. AUSTIN, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the U.S. Food and Drug Administration (FDA) has lifted the full clinical hold on the Company's Phase 2 "RENEW" trial evaluating LTI-03 in patient

    11/3/25 7:30:00 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

    EMA approval covers study sites in Germany and Poland as part of the Company's global Phase 2 RENEW trialTrial will evaluate LTI-03, a first-in-class therapy designed to both reduce lung scarring and promote repair AUSTIN, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has received authorization from the European Medicines Agency (EMA) to initiate the Company's Phase 2 "RENEW" clinical trial of its lead candidate, LTI-03, for the treatment of idiopathic pulmona

    10/9/25 7:30:00 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Rein Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $10.00

    9/22/25 8:32:15 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Rein Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $8.00

    1/28/25 7:16:42 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Voss Capital, Lp bought $423,466 worth of shares (306,050 units at $1.38) (SEC Form 4)

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    10/28/25 6:45:45 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Voss Capital, Lp bought $423,466 worth of shares (306,050 units at $1.38) (SEC Form 4)

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    10/28/25 6:45:45 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Voss Capital, Lp claimed ownership of 1,016,208 shares (SEC Form 3)

    3 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    10/3/25 3:09:44 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Aivado Manuel

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    7/23/25 7:42:24 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    SEC Filings

    View All

    Rein Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

    11/3/25 7:45:11 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rein Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

    10/24/25 5:08:06 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Rein Therapeutics Inc.

    8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

    10/9/25 7:45:46 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care